No abstract available
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antibodies, Neutralizing / biosynthesis
-
Antibodies, Viral / biosynthesis
-
Antigens, CD20 / immunology
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / therapeutic use
-
COVID-19 / immunology*
-
COVID-19 / prevention & control*
-
COVID-19 Vaccines / administration & dosage*
-
Female
-
Humans
-
Immunity, Cellular
-
Immunocompromised Host
-
Lymphoma / immunology*
-
Lymphoma / therapy*
-
Male
-
Middle Aged
-
Multivariate Analysis
-
Rituximab / adverse effects
-
Rituximab / therapeutic use
-
SARS-CoV-2 / immunology*
-
Seroconversion
-
Young Adult
Substances
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Antigens, CD20
-
Antineoplastic Agents, Immunological
-
COVID-19 Vaccines
-
Rituximab
-
obinutuzumab